LeonaBio Inc (LONA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.56-1.82%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LONA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
LONA — private placement
Dated 2026-08-26
Other Events. On August 26, 2026, LeonaBio, Inc. (the “Company”) announced that it had enrolled the 500th subject in its ongoing Phase 3 ELAINE-3 clinical trial (NCT05696626) for lasofoxifene in combination with abemaciclib, a CDK4/6 inhibitor, as a targeted therapy for estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated metastatic breast cancer, following progression on aromatase inhibitors and CDK4/6 inhibitors (the “ELAINE-3 Trial”). In connection with the private placement finan…
Why it matters: Better cash flow is key for funding clinical trials and operations.
Worry ifCash flow from operations will be positive in the next quarters.
Less concerning ifCash flow from operations remains negative or worsens.
Why it matters: Better cash flow is important for paying for clinical trials and daily operations.
Supportive ifCash flow from operations improves from -$20.9M in Q1 2026 to less negative in Q2 2026.
Worry ifCash flow from operations worsens or remains negative in Q2 2026.
Why it matters: If revenue growth picks up, it may signal a positive shift for LeonaBio. The sector is currently maturing, and growth is slowing.
Supportive ifHealthcare sector revenue growth is speeding up. It is getting close to 10% or more.
Worry ifHealthcare sector revenue growth is slowing down. It is now below 10%.
Why it matters: Watching cash levels is important for LeonaBio's ability to fund trials. A drop may mean financial problems.
Worry ifCash, cash equivalents, and investments remain stable or increase from $51.1 million as of Q2 2026.
Less concerning ifCash drops below $51.1 million, which may signal funding problems.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$237 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $823 loss on $10,000 · 8.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,267 loss on $10,000 · 42.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Finishing this acquisition could help LeonaBio grow and add new products.
Supportive ifA press release will confirm that the Sermonix acquisition is complete.
Worry ifThere may be more delays. The acquisition announcement could also be canceled.
Why it matters: Finishing enrollment is important for using lasofoxifene to treat breast cancer. It shows progress.
Supportive ifAbout 600 patients will finish enrollment in the ELAINE-3 trial by Q4 2026.
Worry ifEnrollment does not reach 600 patients by the end of Q4 2026.
Why it matters: Starting this trial shows progress in developing a treatment for ALS. It could expand LeonaBio's pipeline.
Supportive ifPhase 2 proof-of-concept trial for ATH-1105 begins in the second half of 2026.
Worry ifPhase 2 trial does not start as planned in the second half of 2026.
Why it matters: Topline data will show how well lasofoxifene works and its market impact. This is a big step.
Supportive ifTopline data from the ELAINE-3 trial is released in the second half of 2027.
Worry ifTopline data is delayed beyond the second half of 2027.